MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

Panelists highlight that patient advocacy is crucial in improving high-risk acute myeloid leukemia (AML) outcomes by ...

A large new study has confirmed the clinical relevance of a pharmacogenomic score that could help tailor leukaemia treatment ...

Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...

Scientists at Indiana University School of Medicine have identified a new approach that could transform treatment for acute ...

Scientists find link between where you live and childhood leukemia - New research has found that millions of children are at ...

Bleeding gums is a common manifestation in leukaemia, more so in acute leukaemias like Acute Myeloid leukaemia (AML) and ...

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for decitabine/cedazuridine plus venetoclax to treat adults with newly diagnosed acute myeloid leukemia ...

Sellas Life Sciences’ investigational CDK9 inhibitor has scored in a midstage acute myeloid leukemia (AML) study, demonstrating an overall response rate (ORR) more than double the 20% goal.

Acute myeloid leukemia (AML) is rare in pregnancy, progresses fast, and needs to be treated. We explain symptoms, treatment, and outlook for AML in pregnancy.